logo
Scientists Just Found a New, Incredibly Rare Blood Type

Scientists Just Found a New, Incredibly Rare Blood Type

Gizmodo23-06-2025
Step aside A, B, and O—there's a new player in town. Scientists in France have just reported the discovery of a novel, rare blood type, only recorded in a single person to date.
The French Blood Establishment (EFS), the country's sole civilian blood transfusion organization, announced the discovery over the weekend. The blood type, nicknamed 'Gwada negative,' was found in a French woman originally from Guadeloupe. It's the 48th distinct blood group system to be established.
'This discovery was officially recognized in early June in Milan by the International Society of Blood Transfusion,' the EFS said in a statement released on LinkedIn Friday.
The 'Man With the Golden Arm': Blood Donor Who Saved Millions Dies at 88
It's taken a long while for this recognition to happen. Researchers at the EFS first noticed an unusual antibody in the woman's blood in 2011, after she provided a sample for routine examination before a surgery in her early 50s. But they simply didn't have the resources or technology needed at the time to look further into it. Finally, in 2019, they were able to perform 'high-throughput DNA sequencing' of the woman's genetics, which confirmed she possessed a unique blood-related mutation inherited from both her parents.
Her blood type appears to be the result of having both copies of this mutation, since her siblings have one copy and don't have it. The blood type is formally called PIGZ, with Gwada negative being a reference to the woman's Guadeloupean origin (Guadeloupe is an French island region in the Caribbean). So far, she seems to be one of a kind.
'She is the only person in the world who is compatible with herself,' Thierry Peyrard, a medical biologist at the EFS who helped discover the blood type, told the AFP.
Donated Blood Is Safe No Matter a Person's Sex, Large Trial Finds
Blood types refer to the particular combinations of antigens that cover our red blood cells. The most commonly found antigens belong to the ABO blood group, but scientists have discovered over 600 separate antigens that can be sorted into dozens of blood groups. Knowing our blood type is important, since our body's immune system can generate antibodies that attack blood cells from someone with a blood type incompatible with ours. This not only complicates blood donation but pregnancy. So aside from simple curiosity, categorizing Gwada negative and other rare blood types can be medically vital.
'Discovering new blood types means offering patients with rare blood a better level of care,' the EFS said.
Peyrard and his colleagues are now hoping to find others with the woman's blood type, and will first plan to look for it among blood donors in Guadeloupe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism
Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism

Medscape

timean hour ago

  • Medscape

Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism

TOPLINE: Abatacept outperformed hydroxychloroquine (HCQ) in preventing patients with palindromic rheumatism (PR) from progressing to rheumatoid arthritis (RA). METHODOLOGY: Researchers randomly assigned 70 individuals with PR who were seropositive for rheumatoid factor or anti-citrullinated protein antibodies in a 1:1 ratio to receive open-label abatacept (ABA) at 125 mg/week or HCQ at 5 mg/kg/day for 1 year. All patients had symptom durations of over 3 months but under 3 years and were not taking any disease-modifying antirheumatic drugs or glucocorticoids. Patients were followed for an additional year to track RA development. TAKEAWAY: At month 24, three patients (8.8%) in the ABA group progressed to RA compared with 10 patients (27.8%) in the HCQ group (P = .047). Patients treated with HCQ who developed RA generally progressed in the first 12 months of the trial, whereas patients treated with ABA who developed RA did so at the end of the second year. The ABA group also had higher persistent remission rates of PR than the HCQ group (55.9% vs 22.9%). Serious adverse events were uncommon in both treatment groups. IN PRACTICE: 'In patients with recent-onset seropositive palindromic rheumatism, abatacept significantly decreased the rate of RA progression in comparison with hydroxychloroquine at 2 years follow-up,' said study author Raimon Sanmarti, MD, PhD, of the Hospital Clínic de Barcelona, Barcelona, Spain. 'Abatacept is also more efficacious than hydroxychloroquine in the control of symptoms of seropositive palindromic rheumatism.' SOURCE: Sanmarti presented the study in an oral abstract session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. LIMITATIONS: This was an open-label study with a relatively small sample of patients. Over the 2-year trial, eight patients in the HCQ group and five patients in the ABA group exited the trial or were lost to follow-up. DISCLOSURES: The Fundació Clínic per a la Recerca Biomèdica sponsored the study. Sanmarti disclosed financial relationships with Bristol Myers Squibb, AbbVie, MSD, Roche, UCB, Pfizer, Eli Lilly, Gebro, Janssen, Sanofi, Gilead, and Adacyte.

Microaxial Flow Pump Reduces Heart Load in Post-MI Shock
Microaxial Flow Pump Reduces Heart Load in Post-MI Shock

Medscape

time2 hours ago

  • Medscape

Microaxial Flow Pump Reduces Heart Load in Post-MI Shock

TOPLINE: In patients with ST-segment elevation myocardial infarction (STEMI)-induced cardiogenic shock undergoing hemodynamic monitoring with a pulmonary artery catheter, the use of a microaxial flow pump (mAFP; Impella) reduced the intrinsic mechanical work performed by the heart by reducing native cardiac output and pulmonary pressures while maintaining the power output delivered to the body. METHODOLOGY: A previous Danish-German trial showed reduced mortality with early placement of an mAFP in patients with cardiogenic shock following STEMI. In this substudy, researchers analyzed data of 223 patients monitored in the cardiac ICU with a pulmonary artery catheter to determine the effects of the device on hemodynamics in STEMI-induced cardiogenic shock. Patients had been randomly assigned to receive either standard care (n = 98; median age, 67 years; 78% men) or an mAFP plus standard care (n = 125; median age, 65 years; 82% men). Outcomes included cardiac output, mean pulmonary artery pressure, and cardiac power output during the first 48 hours after admission to the cardiac ICU; native cardiac output was defined as the patient's total cardiac output minus the estimated mAFP flow. TAKEAWAY: After the initial 6 hours in the cardiac ICU, cardiac output continued to improve in the mAFP group and remained consistently higher than in the standard care group from 12 to 48 hours (P < .001). Native cardiac output also improved after 6 hours but stayed significantly lower in the mAFP group than in the standard care group. Mean pulmonary artery pressure was initially lower in the mAFP group than in the standard care group (median, 27 vs 31 mm Hg; P < .001) and remained lower at 48 hours. Pulmonary capillary wedge pressure was also lower in the patients with an mAFP. The initial cardiac power output within 3 hours of arrival to the cardiac ICU was 0.56 W in the standard care group vs 0.68 W in the mAFP group (P = .01), which improved over the next 48 hours. The mAFP group required lesser vasoactive and inotropic support than the standard care group for the first 6 hours and had lower mortality at 180 days. IN PRACTICE: 'We consistently found lower pulmonary pressures and a PCWP [pulmonary capillary wedge pressure] during mAFP support, each of which provides confirmation of LV [left ventricular] unloading while on mAFP. Reducing these pressures helps alleviate pulmonary edema, reduce right ventricular afterload, and enhance forward flow,' the researchers wrote. 'By reducing myocardial work and wall stress, unloading may be protective in stunned, postischemic myocardium vulnerable to further insult,' the authors of an editorial accompanying the journal article wrote. SOURCE: This study was led by Jacob Eifer Møller, MD, DMSc, Odense University Hospital, Odense, Denmark. It was published online on June 23, 2025, in Journal of the American College of Cardiology. LIMITATIONS: Pulmonary artery catheter was used more frequently in patients randomized to the mAFP group compared with the standard care group. Data capture may not have been streamlined or complete as this study involved patients who were critically ill, unstable, and had imminent need for treatment. Hemodynamic monitoring was limited to the first 48 hours and did not account for long-term effects or changes. DISCLOSURES: The original trial was supported by the Danish Heart Foundation and Abiomed. Several authors reported receiving research, educational, and/or travel grants, speaker fees, and honoraria; serving on advisory boards; holding stock options; and having other financial ties with various pharmaceutical, healthcare, and other companies, including Abiomed, Novo Nordisk Foundation, and Boston Scientific. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Certain Plant-Based Foods May Cut Crohn's Disease Risk
Certain Plant-Based Foods May Cut Crohn's Disease Risk

Medscape

time2 hours ago

  • Medscape

Certain Plant-Based Foods May Cut Crohn's Disease Risk

TOPLINE: A high combined intake of fruits, vegetables, legumes, and potatoes was associated with a reduced risk for Crohn's disease — driven largely by specific foods such as apples or pears, bananas, mushrooms, and onions or garlic. Alternatively, a high intake of potatoes was associated with an increased risk for ulcerative colitis. METHODOLOGY: The International Organization for the Study of Inflammatory Bowel Disease recommends eating more fruits and vegetables for their fiber benefits, but current guidelines do not distinguish between subcategories despite their differing compositions and potential effects on inflammatory bowel disease (IBD) risk. Researchers analyzed data of 341,519 participants without IBD (mean age, 52.1 years; 70% women) from a popular European cohort to evaluate how consumption of individual fruits, vegetables, legumes, and potatoes influenced the risk for Crohn's disease and ulcerative colitis. At baseline, validated food frequency questionnaires were used to assess dietary intake of fruits, vegetables, legumes, and potatoes (including other tubers). Participants in the lowest vs highest quartiles had median daily intakes of 291.6 vs 840.9 g/d of combined fruits, vegetables, legumes, and potatoes; 17.0 vs 100.3 g/d of apples/pears; 6.6 vs 14.0 g/d of bananas; 2.1 vs 6.2 g/d of mushrooms; 4.1 vs 11.9 g/d of onions or garlic; and 64.7 vs 82.1 g/d of potatoes. TAKEAWAY: The median follow-up period was 13.4 years, during which 149 participants developed Crohn's disease and 379 developed ulcerative colitis. A higher combined intake of fruits, vegetables, legumes, and potatoes was associated with a lower risk of developing Crohn's disease (highest vs lowest quartile; adjusted hazard ratio [aHR], 0.44; 95% CI, 0.26-0.76) but not ulcerative colitis (aHR, 1.07; 95% CI, 0.76-1.50). A subsequent post hoc analysis showed that the pooled intake of apples or pears, bananas, mushrooms, and onions or garlic was linked to a comparable risk reduction for Crohn's disease as total fruit, vegetable, legume, and potato intake (highest vs lowest quartile; pooled aHR, 0.58; 95% CI, 0.33-1.02). However, a higher intake of potatoes was associated with a higher risk of developing ulcerative colitis (highest vs lowest quartile; aHR, 1.51; 95% CI, 1.05-2.17). IN PRACTICE: 'In conclusion, we found that high combined intake of fruits, vegetables, legumes, and potatoes is associated with a lower risk of developing CD but not UC. This was particularly apparent for apple/pear, banana, mushrooms, and onion/garlic intakes. A higher risk of UC was observed for a higher intake of potatoes,' the authors of the study wrote. SOURCE: This study was led by Antoine Meyer, MD, PhD, Université Paris-Saclay, Villejuif, France. It was published online in the American Journal of Gastroenterology. LIMITATIONS: This study relied on food frequency questionnaires measured only at baseline, which may not have fully captured dietary changes over time. The mostly older, female population may not have represented the broader European or younger populations. As with all observational studies, residual confounding from unmeasured factors could not be ruled out. DISCLOSURES: The cohort was supported by the International Agency for Research on Cancer, the Department of Epidemiology and Biostatistics, School of Public Health, and other sources. Some authors declared receiving speaker fees, grants, consulting fees, and travel support from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store